Company news

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) news

Sensei Biotherapeutics, Inc. news releases on 6ix. Latest, Jun 15, 2026: Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused…

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) news

Press releases & updates

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

Egle Therapeutics Appoints John Celebi as Chief Executive Officer

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

Sensei Biotherapeutics : Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sensei Biotherapeutics to Present at Upcoming Conferences

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Im...

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth Conference